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Abstract
The Biopharmaceutics Classification System (BCS) classifies pharmaceutical compounds based
on their aqueous solubility and intestinal permeability. The BCS Class III compounds are
hydrophilic molecules (high aqueous solubility) with low permeability across the biological
membranes. While these compounds are pharmacologically effective, poor absorption due to low
permeability becomes the rate-limiting step in achieving adequate bioavailability.
Several approaches have been explored and utilized for improving the permeability
profiles of these compounds. The approaches include traditional methods such as prodrugs,
permeation enhancers, ion-pairing, etc., as well as relatively modern approaches such as
nanoencapsulation and nanosizing. The most recent approaches include a combination/
hybridization of one or more traditional approaches to improve drug permeability. While some of
these approaches have been extremely successful, i.e. drug products utilizing the approach have
progressed through the USFDA approval for marketing; others require further investigation to be
applicable. This article discusses the commonly studied approaches for improving the
permeability of BCS Class III compounds.
Keywords: Permeability, BCS Class III, Prodrugs, Ion-pairing, Counterion, Nanotechnology,
Liposome, Permeation enhancer

Introduction
The Biopharmaceutics Classification System (BCS) of drugs has been developed primarily to
provide a scientific approach for classifying oral immediate release drug formulations based on
aqueous solubility and intestinal permeability, in combination with the dissolution properties [1].
Pharmaceutical compounds that belong to the BCS Class III are predominantly hydrophilic and
have a poor permeability profile. This classification can be further extended to include new
chemical entities (NCEs) with similar properties. Molecules in this class are known to
demonstrate excellent pharmacological efficacy in-vitro, but present a challenge when
formulated into orally administered dosage forms due to permeability related issues[2]. Over the
years, our laboratories have worked with BCS Class III and similar molecules to address
permeability issues; mainly by prodrug and permeation enhancer based approaches. Besides that,
researchers have explored several other approaches with an aim to tackle the issue of low drug
permeability without compromising critical solubility [3, 4, 5, 6, 7]. Among the more commonly
studied approaches include prodrugs, permeation enhancers, ion-pairing, and other
nanotechnology-based approaches. With this review article, we are bringing the foremost
approaches under one umbrella to help facilitate further research on BCS Class III or analogous
molecules.
This review highlights the different approaches utilized in recent years to increase the
permeability of BCS Class III compounds. The article is organized such that the more
established approaches are discussed earlier, followed by the relatively newer approaches. Each
approach is discussed with respect to its concept, mechanism, advantages/drawbacks, and
applicability to the oral and non-oral dosage forms. Specific examples of the compounds
currently being researched, or currently being marketed, are provided as applicable.
Approaches for improving permeability
Prodrugs
Prodrugs have been described earlier as the derivatives of drug molecules that undergo an
enzymatic or other biochemical transformation in-vivo in order to release its pharmacologically
active parent drug [8]. The prodrug approaches have been historically utilized for improving the
physicochemical and pharmacokinetic properties of pharmacologically active agents. Prodrugs
provide opportunities to overcome several formulation and drug delivery barriers such as poor
aqueous solubility, physical and chemical instability, insufficient oral absorption, rapid pre-

systemic metabolism, and inadequate tissue permeability [8]. An ideal prodrug is one that is
readily transported to the desired site, selectively cleaved to release the active drug, and is
retained at the site of action.
Improving passive diffusion
For a majority of drugs, the permeability across cell membranes is known to be significantly
influenced by their partition coefficient, i.e. their log P value besides other factors like molecular
size and concentration gradient. Previous reports have hypothesized a sigmoidal relationship
between the log P value of drugs, and their cell membrane permeability[9]. Therefore, among of
the more commonly employed prodrug strategies for improving the absorption of poorly
permeable drugs is to increase the lipophilicity (log P) of drug [10]. Although, the use of log P to
understand permeability is an over-simplification of the complex process, some correlation exists
as majority of oral drugs fall between 1-5 log P values. A few outliers with atypical permeability
behaviors are generally attributed to either active transport, paracellular transport, and/or the
involvement of other influx-efflux mechanisms. The log P value of drugs can be increased to a
certain extent by masking the hydrophilic, non-ionizable, or ionizable functional groups such as
carboxylic, hydroxyl, amine, phosphate, and carbonyl groups. Typically, these functional groups
are modified into carbonate esters, carbamates, amides, phosphate esters and oximes, which are
frequently represented in marketed prodrugs. Ester prodrugs are among the most commonly
designed prodrugs for increasing the lipophilicity, and thus enhancing the passive membrane
permeability of water-soluble drugs by masking the charged functional groups. Once within the
physiology, the ester bond is readily hydrolyzed by the esterases found in the blood, liver,
tissues, and other organs. Figure 1 shows a few of the prominent examples of ester prodrugs
including, enalapril (ethyl ester), pivampicillin (pivaloyloxymethyl ester), adefovir dipivoxil (a
diester), and famicilovir (prodrug of penciclovir) [8].
The use of enzymatically labile spacer group moieties is one of the approaches
researchers have utilized in order to help the drugs resist non-enzymatic hydrolysis during
passive diffusion. The acyloxyalkyl compounds formed as a result serve as neutral lipophilic
prodrugs capable of traversing the cell membranes by passive diffusion, followed by intracellular
reversion to the parent di-acid after the cleavage of acyl group [11]. This is rapidly followed by
the release of an aldehyde, thereby eliminating the spacer group. Methylene is a standard spacer

group, owing its popularity to the lack of chirality issues [12]. Researchers have applied this
approach to synthesize prodrugs for a variety of antiviral agents, including adefovir.
Adefovir exists as a di-anionic compound at physiological pH, rendering it extremely
polar. This highly polar nature of adefovir prevents it from undergoing passive diffusion across
cellular membranes and intestinal mucosa, thus resulting in poor oral bioavailability. An
approach for improving membrane permeability of adefovir involved esterification of the polar
phosphonic acid group, resulting in a prodrug, adefovir dipivoxil (Figure 1), a compound with
two pivaloyloxymethyl moieties. The masking of the polar phosphonic acid group resulted in an
increase in the lipophilicity of adefovir, thereby allowing the prodrug to traverse the cell
membranes by passive diffusion [11]. The oral bioavailability of adefovir dipivoxil in humans
was found to be significantly higher (59 %), compared to that of adefovir (12 %) [13]. Besides,
this prodrug of adefovir demonstrated significantly increased antiviral activity in-vitro,
indicating increased penetration into infected cells. The clinical (human) safety and efficacy of
adefovir dipivoxil was later established, and in 2002, an oral tablet formulation (Hepsera®,
Gilead Sciences, Inc., USA) was approved by the USFDA for the treatment of hepatitis B
infections. Perioli et al synthesized and evaluated prodrugs of several NSAIDs according to
the chemical delivery approach developed by Bodor, with a goal to increase their
permeability across the blood brain barrier (BBB) [14]. The prodrugs were prepared by
attaching the carboxylic group of NSAIDs to the 1,4-dihydro-1-methylpyridine-3carboxylate moiety, which acts as a carrier, via an amino alcohol bridge. The prepared
prodrugs were found to be promising candidates for improved BBB permeability.
Improving active transport
Prodrugs targeted towards specific membrane transporters are designed to have structural
features that would allow them to be taken up by one of the endogenous transporters present at
the intestinal epithelium [8]. Targeting specific endogenous transporter is critical for highly
polar, charged compounds that may not demonstrate passive diffusion as a major absorption
mechanism. Unlike passive diffusion that is influenced mainly by log P value, active transport of
drug molecules depends on a wide variety of specific endogenous transporters. In fact, different
classes of transporters such as, solute carrier family (SLC) and ATP-binding cassette (ABC)
transporters have been explored with an aim to increase oral absorption [15]. Transporters such
as organic cation transporter (OCT), organic anion transporter (OAT), bile acid transporters,

cholesterol transporter (ABCG5/8), monocarboxylate transporter 1 (MCT-1), etc. have been
reported in literature to improve oral bioavailability of drugs [16, 17].
These transporters are known to have a high transport capacity and a broad substrate specificity.
A detailed discussion of all transporters is beyond the scope of this article, however readers are
encouraged to follow the references for detailed information. A few examples are provided to
illustrate the importance of transporters for increasing the permeability of drug molecules. Wellknown examples of prodrugs that are designed to exploit such transporter-mediated absorption
include valacyclovir, valganciclovir, and gabapentin.
Peptide transporters are among the most widely distributed transporters throughout the
small intestine. Valacyclovir is a l-valyl ester prodrug of acyclovir that is used for the treatment
of herpes, varicella zoster, and cytomegalovirus (Figure 1). This orally administered prodrug was
developed to improve the bioavailability of acyclovir, and is a classic example of utilizing the
carrier-mediated transport. The absolute oral bioavailability of acyclovir (the parent drug) from
this prodrug was found to be 54.4%, a 3- to 10-fold increase compared to that observed with the
administration of its parent molecule [18]. The observed increase in the oral bioavailability of
acyclovir is reported to be the result of favorable transport of valacyclovir into the gut lumen by
an endogenous oligopeptide transported (PEPT-1) [19, 20, 21].
A prodrug approach exploiting the carrier mediated transport was recently explored by
our laboratory[4]. 4-guanidine oseltamivir carboxylate (GOCarb), Figure 1, is a potential
influenza treatment that is reported to have a higher potency compared to oseltamivir carboxylate
(OC). OC was earlier modified to produce an ethyl ester prodrug, which showed significantly
higher membrane permeability, and was later approved as Tamiflu®. However, emergence of
resistant strains and the need for better therapeutic outcomes lead us to target GOCarb. Simple
esterification approach was not successful with GOCarb - a highly polar BCS Class III type
molecule. A carrier-mediated approach was then used with GOCarb, which involved linking lisoleucyl, l-leucyl, or l-valyl with the parent molecule to obtain amino acid prodrugs of GOCarb
(Figure 1). These prodrugs of GOCarb demonstrated a significant advantage with respect to
PEPT-1 mediated uptake, increasing its membrane permeability and bioavailability (Figure 2)[4].
Another example involving MCT-1 and sodium dependent multivitamin transporter
(SMVT) is XP13512, a novel prodrug of gabapentin. The parent drug, gabapentin, is a structural
analog of γ-aminobutyric acid (GABA) that is currently approved by the USFDA for the

treatment of epilepsy and post-herpetic neuralgia. This drug is thought to be absorbed from the
intestines of mammals by a low-capacity solute transporter mainly located in the upper small
intestine. Due to the saturation of this transporter, gabapentin demonstrates dose-dependent
pharmacokinetics and high inter-patient variability, i.e. its bioavailability ranges from 30-60% of
the dose (300 mg) used to treat neuropathic pain [22].
(±) − 1 − {[(𝛼𝛼 − 𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖ℎ𝑜𝑜𝑜𝑜𝑜𝑜) 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐] 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎ℎ𝑦𝑦𝑦𝑦 } − 1 −

𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐ℎ𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 (XP13512, or gabapentin enacarbil), was later designed to increase

the absorption of gabapentin throughout the intestine by high-capacity nutrient transporters

MCT-1 and SMVT. Gabapentin shows no significant interactions with either MCT-1 or SMVT,
probably due to its charged amine group; however, its prodrug XP13512, combines the
properties required for recognition by both high-capacity transporters, allowing for its direct
uptake across human embryonic kidney (HEK) cells [22]. The transcellular flux of XP13512
across CACO-2 cell monolayers was observed to be five times greater in the apical to basolateral
direction, further suggesting that the prodrug interacts with both MCT-1 and SMVT. XP13512 is
rapidly converted to gabapentin in the intestinal and liver tissues of animals and humans. The
artificial membrane permeability studies at pH 6.5 and 7.4 with XP13512 showed that this
prodrug may also have some ability to passively diffuse across cell membranes depending on the
local pH. The 𝑝𝑝𝐾𝐾𝑎𝑎 of XP13512 is 5, suggesting that passive diffusion plays only a minor role, if

at all, in its intestinal absorption. This prodrug was approved by the USFDA for the treatment of
Restless Legs Syndrome (RLS) in 2011, and for the treatment of post-herpetic neuralgia in adults
in 2012.
As discussed above, utilizing the active and passive mechanisms of transport have proven
to be highly successful approaches for improving the permeability, and the overall bioavailability
of BCS Class III or similar compounds. This can further be extended to address permeability
issues of BCS Class IV molecules. Among the more popular formulation approaches for
improving the membrane permeability of these compounds is the use of permeation enhancers.
The applications of permeation enhancers as a formulation strategy form to increase drug
permeability are discussed below.
Permeation enhancers
Permeation enhancers (PEs), also known as absorption enhancers are chemical moieties included

in the formulations to facilitate the absorption of drugs from pharmaceutical products. PEs can

positively influence drug absorption by a variety of mechanisms such as modifying mucus
rheological properties, altering fluidity of gastric membrane, inhibiting enzymes (e.g.
proteases) and inhibiting efflux pumps [23]. PEs have been studied for several years in efforts
to develop non-parenteral formulations for peptides, proteins, and other pharmacologically active
compounds that have less than optimal membrane permeability [24]. PEs can be useful in
optimizing drug delivery for oral as well as transdermal/transmucosal (e.g. nasal, buccal,
sublingual, rectal etc.) absorption sites. However, safety in humans with these agents in always
a concern and these agents need to be carefully evaluated before they can be approved by FDA.
This review is limited to the discussions regarding the enhancement of oral absorption of drugs
with poor permeability. Several PEs currently under investigation are illustrated in Table 1. This
table also addresses the regulatory status of some of the permeation enhancers with USFDA.
Most of the research on permeation enhancers is focused on the preclinical evaluation of
permeability enhancement via in-vitro studies and possible toxicity.
Table 1: Common permeation enhancers
Permeation enhancer
Sodium dodecyl
sulphate[25]

α

N -deoxycholyl-L-lysyl
methylester[26]

Rhamnolipids[27]

Phospholipid
hexadecanol tyloxapol
(PHT)[9]
CriticalSorb™
(absorption enhancer
based on Solutol®
HS15)[30]

Proposed mechanism
Decreases Trans Epithelial
Electrical Resistance (TEER),
and facilitates opening of the
tight junctions
Increases the lipophilicity of
drug; drug-complex interacts
with the bile acid transporter
and increases absorption

P-gp inhibition

Direct interaction with the
tight junctions between cells
resulting in intercellular
permeation of peptide drugs
Decrease in TEER; P-gp
inhibition (combination of
increased paracellular and
transcellular flux)

Remarks
• Toxicity to the intestinal mucosa
• Included in the FDA inactive
ingredients guide (dental preparations;
oral capsules, suspensions, and tablets;
topical and vaginal preparations)
• Toxicity to the gastrointestinal mucosa
• Insulin carrier to enhance oral delivery
• Demonstrated to be safe in cell viability
hemolysis assays
• Low toxicity, surface active properties
and antimicrobial activities against
several microbes (Bacillus cereus,
Micrococcus luteus, Staphylococcus
aureus, Listeria monocytogenes)
thereby showing promising applications
in pharmaceuticals and therapeutics[28,
29]
• No significant acute toxicity observed
in the Lactose dehydrogenase (LDH)
release assay
• No evidence of cytotoxicity in tissue
histology, and CACO-2 assay

• Pharmaceutically acceptable excipient
approved by the FDA as generally
regarded as safe (GRAS)

Chitosan[31]

D-octaarginine-linked
polymers[32]

Opening of the epithelial tight
junctions (TJ), and paracellular
• No apparent toxicity
transport via translocation of
JAM-1 (a trans-membrane TJ
• FDA approved
protein) resulting in the
disruption of TJs
• Polymer-induced uptake is significantly
suppressed by 5-(N-ethyl-N-isopropyl)
amiloride, which is an inhibitor of
Polymer induced
micropinocytosis
macropinocytosis
• Currently being investigated as a novel
penetration enhancer[33]

Thiolated
polyacrylates[2]

P-gp inhibition

Thiolated
polycarbophils/
glutathione[36]

Protection against degrading
enzymes and facilitation of
transport across intestinal
membranes

Partially quarternized
poly(methacrylate)
terpolymers[38]

pH-dependent decrease in
TEER values

Spermine (SPM) polyacrylic acid (PAA)
polymer ion-pair[39]

Decreased TEER; paracellular
permeation via opening of
tight junctions

FDA approved for topical route (i.e.
patch, film CR), also shown to improve
the uptake of hydrophilic macromolecules
from the GI tract.[34, 35]
• Included in the FDA Inactive Database
(buccal (tablet) and ophthalmic
(solution) preparations; topical patches;
vaginal gel)
• PCP-Cys/GSH system might be a
promising tool for the oral
administration of oligonucleotides as it
allows a significant protection toward
degrading enzymes and facilitates their
transport across intestinal
membranes[37]
• Reversible decrease in TEER values;
recovery of cells after 6 hours
• Partially quarternized poly
(methacrylate) terpolymers (QBBMCs) have been synthesized, based
on the basic butylated methacrylate
copolymer (BBMC/EUDRAGIT E),
which is an excipient approved by the
FDA[26]
• Polyacrylic acid, sodium salt is listed as
a food additive by the FDA
• Cytotoxicity studies in Caco-2
monolayers revealed the safety of the
delivery system in the concentration
range used for permeation
enhancement.[40]
• Reversible opening of tight junctions;
reversible decrease in TEER values

Sodium Caprate[41]

Opening of tight junctions;
perturbation of membrane
lipid or protein

Decanoyl Carnitine[42]

Opening of tight junctions
(TJ); perturbation of
membrane lipid or protein

• Increased intracellular calcium levels to
induce contraction of calmodulindependent actin filaments
• FDA approved
Decrease in the intracellular pH and the
ATP levels. Intracellular acidosis.
Increases in the calcium levels

Surfactants are the most frequently utilized wetting agents in pharmaceutical
formulations for improving the dissolution and absorption of poorly soluble drugs. While
surfactants are also considered as efficient enhancers, their use in formulations is limited due to
potential adverse effects on the integrity of the intestinal mucosa. Additionally, they can interact
with native surfactants (biles acids and phopspholipids) and can have add-on effect. Low
molecular weight ionic surfactants like sodium dodecyl sulfate (SDS) are among the most
commonly used classes of compounds for this purpose [43]. SDS has been reported to have
significant effects on the paracellular permeability in CACO-2 cells by decreasing the TEER
(Transepithelial electrical resistance) values, increasing the intracellular calcium levels, and
opening of the tight junctions [25].
Gundogdu et al. assessed the effects of SDS in improving the permeability of
fexofenadine hydrochloride (FEX) using CACO-2 cells.[44] FEX contains a basic amine, and an
acidic carboxylic acid group, which results in FEX having a pH-dependent aqueous solubility.
FEX also demonstrates a low, and a concentration-dependent intestinal permeability in CACO-2
cells in-vitro. Using TEER value as a standard indicator of permeability, the study results
showed that exposing the cell monolayers to SDS for two hours resulted in a significantly
increased permeability of FEX. The study also emphasized the importance of TEER value in
predicting the permeation-enhancing effects of surfactants like SDS. The observed improvement
in the drug solubilization was attributed to two mechanisms: improvement in the wetting
characteristics of the drug, and possibly a micellar solubilization of the drug. The CACO-2
permeability of FEX from the apical to basolateral, and basolateral to apical direction was also
found to significantly increase with increasing SDS concentration (10 μM - 50 μM). At the
concentrations assayed, SDS was thought to increase the FEX permeability by relaxing the tight
junctions while maintaining the integrity of the CACO-2 cell monolayer.
𝑁𝑁 𝛼𝛼 − 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑ℎ𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 − 𝐿𝐿 − 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 − 𝑚𝑚𝑚𝑚𝑚𝑚ℎ𝑦𝑦𝑦𝑦 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 (DCK) is a permeation enhancer of

synthetic origin. DCK is composed of a hydrophobic domain from deoxycholic acid, and a

positively charged lysine that facilitates the ion-pairing interactions with anionic drugs. Such
ion-pairing interactions could result in an improved absorption of drugs with poor permeability
profile. DCK is also known to interact with a bile acid transporter in the intestinal membrane that
could play a role in the enhancement of oral absorption of several drugs. Park et al. investigated
the influence of DCK as a permeation enhancer on the permeability of ibandronate, a drug used
in the treatment of osteoporosis [45]. Ibandronate is a highly potent nitrogen-containing
bisphosphonate with a good safety and a tolerability profile. However, due to its poor absorption
from the GI tract after oral administration, a relatively high dose (50mg/day, up to 96 weeks) is
required to be administered to achieve therapeutic effectiveness. Park et al. synthesized
ibandronate-DCK complex and evaluated the in-vitro permeability, and in-vivo bioavailability of
the prepared complex in comparison to pure ibandronate in laboratory animals. The in-vitro
permeability assessment was carried out using a vertical Parallel Artificial Membrane
Permeability Assay (PAMPA) system. As compared to the parent drug, the prepared
ibandronate-DCK complex demonstrated a significantly higher permeability of ibandronate,
suggesting that ionic complexation with DCK can enhance the partition of ibandronate into the
lipophilic membranes. The amphiphilic nature of DCK was thought to impart lipophilicity to
ibandronate molecule without any chemical alteration, resulting in the observed increase in its
absorption. The prepared ibandronate-DCK complex (1:2) was additionally analyzed for
bioavailability after intra-jejunal administration in rats. The results showed that the prepared
ibandronate-DCK complex exhibited 2.8- to 4.3-fold increases in the Cmax and AUC values
compared to those of pure ibandronate. Thus a significant increase in the relative bioavailability
of ibandronate due to its complexation with DCK was observed [45].
Chitosan is a linear polysaccharide composed of randomly distributed β-(1-4)-linked Dglucosamine (de-acetylated unit) and N-acetyl-D-glucosamine (acetylated unit). It is a non-toxic,
biocompatible, and biodegradable polymer, commercially prepared by deacetylation of chitin.
Chitosan has been shown to be a useful excipient in a variety of drug delivery systems. The
amine groups present in the polymer have been explored for its role in imparting permeation
enhancement, controlled release, mucoadhesion, transfection, and inhibition of efflux pumps, etc.
properties in pharmaceutical dosage forms. In its role as a permeation enhancer, chitosan is
reported to effectively open the epithelial tight junctions, allowing paracellular transport of the
compounds via translocation of the junction adhesional molecules [46]. Chitosan is also reported

to decrease the TEER values of the cell monolayers, and increase the paracellular permeability of
compounds across them [47, 48]. Additionally, the disruption of the tight junctions by chitosan is
shown to be a reversible process, ensuring the safety of its use as a permeation enhancer.
There are some studies in literature documenting the use of inorganic materials to
alter physiochemical property of a drug. Literature has shown the use of inorganic
materials such as layered double hydroxides; Perioli et al prepared hydrotalcite like
compounds (HTlcs) viz. MgAl-HTlc-FURO to improve furosemide dissolution. The study
showed that furosemide dissolution was enhanced with these complexes by homogenously
dispersing the drug and forming a molecular film that could be defined “shell-liquid state”,
in the nanospaces of the interlayer region [49]. While this study was focused on
enhancement of drug dissolution, in a later study the authors evaluated the influence of
these complexes in enhancing the permeability of furosemide [50]. The authors’ main goal
was to assess gastric mucus rheology and drug flux across gastric mucus layer in vitro.
They also carried out permeation assays using the artificial membrane (in vitro) and
porcine gastric mucosa (ex vivo). While the results obtained from artificial membrane did
not correlate well, the study found a significant increase in furosemide permeability with
MgAl-HTlc-FURO, when compared to furosemide alone. While this was an interesting
study demonstrating the use of inorganic materials to enhance bot solubility and
permeability of a compound, such studies are few and far between, and more inorganic
compounds such as these need to be explored to understand their influence on the
mechanistics of drug permeability.
Current Status of permeation enhancers
As shown in Table 2, significant advances have been made in the utilization of permeation
enhancers to improve drug absorption in transdermal formulations, and several transdermal drug
products using this approach have been approved by the USFDA. While the scientific merit
regarding the use of this approach in oral formulations has been established in the literature,
currently no oral drug product is approved for marketing. One of the barriers to the use of
permeation enhancers in oral formulations is the lack of their established safety profile in
advanced clinical trials. In recent years, a few drug products utilizing permeation enhancers for
increasing oral drug delivery are either on the threshold of being approved, or have advanced
through various stages of clinical trials (Table 2) [24].

Table 2: Permeation enhancers in development/market
Enhancer/technology
Drug/drug product
Cyclopentadecalactone (CPENasulinTM (nasal
215)[51]
insulin)
Sodium N-[8-(2Eligen B12TM (oral
hydroxylbenzoyl)amino] caprylate
vitamin B12)
(SNAC)[52]
Gipet® (medium chain fatty acids,
Almerol™ (MER-103)
salts, and derivatives)[53]
(alendronate)
Antisense
Sodium caprate[54, 55]
oligonucleotide
Sodium caprylate[56, 57]
Octeotride
CapsulinTM (oral
AxcessTM (GRAS excipients)[58]
insulin)
(ChiSys®) Chitosan[59]
Intranasal apomorphine
®
Nexact - Dodecyl-2-N,NFemprox® (Topical
dimethylamino propionate
Alprostadil Cream)
(DDAIP)[60]

Company
CPEX Pharmaceuticals,
Inc.
Emisphere Technologies,
Inc.
Merrion Pharmaceuticals
Ionis Pharmaceuticals, Inc.
Chisama, Inc.
Diabetology, Inc.
Archimedes Pharma
Apricus biosciences, Inc.
Nexmed (U.S.A.), Inc.

Ion-pairing
The use of counterions, or ion-pairing method to improve the passive permeability have been
researched extensively in the past three decades [3, 19, 20, 61, 62]. The ion-pairing approach
works primarily by complexing the molecule of interest with oppositely charged ionic species,
resulting in an overall neutral ion-pair that increases lipophilicity, the membrane permeability,
and the absorption of the molecule [63, 64]. Unlike the prodrug approach where the permeability
enhancement is achieved via formation of a new chemical entity, the complex formed by ionpairing is held together as a single unit by coulombic attractive forces rather than covalent
bonding [42]. As stated above, the ion-pairing approach works by neutralizing the charge on the
drug molecules to allow passive diffusion of the ion-pair complex through biological
membranes. Assuming quasi-equilibrium conditions, this approach would follow the simple rules
of the association constant as shown in the Figure 3, and equation 1 below, where [BH +]
represents the drug and [A-] represents the counterion.

𝐾𝐾 =

[𝐵𝐵𝐵𝐵+𝐴𝐴−]
[𝐵𝐵𝐵𝐵+][𝐴𝐴−]

(1)

The common advantages and drawbacks of this approach are summarized in Table 3.
As shown in this table, a major concern with utilizing the ion-pairing approach for permeability
enhancement is the possibility of having insufficient and/or weak ionic interaction, which may
result in the complex dissociating during the absorption phase through the biological membranes.
This emphasizes the requirement of a high association constant (K) for these interactions.
Table 3: Advantages and drawbacks of ion-pairing approach
•
•
•
•
•

Advantages
Non-prodrug formation of complex; thus
do not requiring enzymes for activation.
Eliminates the necessity of active
transport for absorption.
Complex formed dissociates easily after
absorption.
Equilibrium may be modified to enable
complex absorption followed by facile
dissociation of available drug.
Additives which may compromise
membrane integrity, and lead to toxicity
are not required

Drawbacks
Possibility of premature complex
dissociation during membrane permeation
due to weak non-covalent interactions.
• Many ion-pairing agents utilized may not
be suitable for human intake due to known
membrane irritation and/or toxicity
challenges.
• Overutilization of counterions may result
in the formation of micelles, which may
exacerbate the poor permeability issues.
• Concentration-dependent permeability
enhancement may lead to toxicity at high
levels
• Limited range of target partition
coefficient: the Log P value of the ion-pair
complex required to be between 2 and 5 to
facilitate passive membrane permeability.
Among the more commonly utilized counterion is 1-hydroxy-2-napthoic acid (HNAP).
•

This counterion, due to its high lipophilicity, relatively strong binding constant, and a history of
prior use with drugs such as salmeterol, zanamivir, and oseltamivir makes it an ideal agent to
counterbalance the high polarity of several BCS Class III drugs [5, 6]. Miller et al. utilized
HNAP as a counterion to prepare ion-paired complexes of the oral drugs with poor intestinal
permeability such as zanamivir heptyl ester (ZHE) and guanidine oseltamivir (GO) [6]. The
study results showed a significant (up to 3.7 log units) increase in the lipophilicity of the drugs
due to ion-pairing. Furthermore, the study demonstrated the enhancement of permeability by
plotting a the apparent partition coefficient (Papp) of CACO-2 against the concentration of
HNAP, and developing a quasi-equilibrium transport model with a linear relationship of the

slope close to 1. As shown in the Table 4, each formulation may utilize different types of
counterion approaches to improve permeability.

Table 4: Common ion-pairing agents
Counterion
Counterion type
Trifluoroacetic acid
Anionic ion-pairing
(TFA)[65]
Heptafluorobutyric acid
(HFBA),
Anionic ion-pairing
Pentafluoropropionic acid
(PFPA), phosphoric acid[66]
1-hydroxy-2-napthoic acid
Anionic ion-pairing
(HNAP)[6]
Tetraheptylammonium
bromide (THAB),
Phase-transfer
Tetrabutylammonium iodide catalyst
(TBAI)[67]
Hexadecyldimethylbenzyl
Absorption
ammonium chloride,
enhancer
Hexylsalicylic acid[38]

Remarks
Reduces the pH of aqueous mobile phase
Increases the lipophilicity of the
compound
Increases the partition coefficient (LogP)
of the compound
Increases zeta potential
Increased the lipophilicity and
bioavailability of a beta-lactam
antibiotic, cefpirom

Although this manuscript is mainly focused on approaches to improve oral permeability,
these principles can be extended to topical, as well as parenteral formulations. Understanding the
mechanistic principles of enhanced permeability of a given approach is important, and can help
extrapolate this information to different routes of administration. A significant amount of ion
pairing approach is applied to transdermal formulations. Counterions can serve as neutralizing
agents by binding with the drug molecules via Coulomb forces, reducing their polarity, and
promoting their transmembrane permeation. The ion-paired complex can then dissociate portabsorption, permitting drug molecules to diffuse into the epidermal and dermal tissue layers [40,
68]. Megwa et al. studied the influence of the extent of ion-pairing with alkylamines and

quaternary ammonium ions on the in-vitro transmembrane permeability of salicylates by
measuring the conductivity of the penetrant solution [69]. The study showed that an increase in
the extent of ion-pairing neutralized the overall charge on the molecule, resulting in an increase
in the flux of the drug across the membrane.

There are several other examples where counterion approach has increased transdermal
permeability [70, 71]. There are also reports in literature where the ion-pairing approach have
been explored for ocular formulations [72]. As mentioned above, exploring approaches utilized
in non-oral route of administration can assist in identifying counter ions suitable for oral use.
While studies indicating conceptual success of ion-pairing in improving the permeability of
drugs are frequently found in scientific literature, additional investigations are required to further
this concept to clinical trials, resulting in commercially successful products.
Nanotechnology-based approaches
In the recent years, nanotechnology based approaches are among the most aggressively
researched, for enhancing the delivery of pharmaceutical drug formulations. Due to the perceived
advantage of small particle size (≤100nm) in increasing transmembrane permeability,
nanotechnology based products are presumed to provide a significant improvement in the
bioavailability of several drugs [73]. Several studies have been reported that link the biotoxicity of nanoparticles to their small particle size. However, more comprehensive studies
have shown that nanoparticle-induced bio-toxicities are a result of a complex interplay of
the size, shape, surface chemistry, and the charge on the particles [74]. This review is
focused purely on the merits of nanotechnology in aiding the drug permeability and
bioavailability. The section below discusses current advances in the use of nanotechnologybased approaches for the improvement of drug permeability, and their overall bioavailability.
Nanoparticles
The use of nanoparticles for increasing the permeability of drugs has been a subject of current
scientific and biomedical research. Originally stemmed from the focus of delivering anti-cancer
agents, this approach has gained popularity due to its reported ability to allow delivery of nucleic
acids, peptides, etc. for the treatment of several diseases [75]. The emergence of this approach
also stems from the drawbacks associated with the therapeutic interventions using
macromolecules or micromolecules. Most macromolecular drugs are reported to have a high risk
of proteolytic and/or hydrolytic degradation, resulting in low bioavailability and a shorter halflife. Micromolecular anticancer drugs are associated with toxic side effects or unsuitable biodistribution [75]. Additionally, small-molecule anticancer agents may quite often be hydrophilic
in nature, and suffer from poor permeability similar to that observed with BCS Class III drugs.

Thus, the primary aim of the nanoparticle-based approaches is to improve the permeability
profiles of drugs, in addition to preventing the undesired side effects.
The nanoparticle based approach works by encapsulating the drug molecule in polymeric
nanoparticles with a goal to overcome several challenges such as hydrophilicity, poor cellular
penetration due to size, biological degradation, and toxicity of the drug molecules [75]. In
addition, the significant reduction of the particle size to ≤100 nm is known to result in dramatic
changes in the pharmacokinetics of the drug molecules, particularly the drugs’ permeability and
delivery efficiency [31]. Since low permeability is the greatest challenge for drugs in BCS Class
III, the nanoparticle based approach provides a promising new direction for formulating these
drugs. Nanoparticle based formulation of drugs can be achieved in several ways, i.e. entrapment
of drug molecules in polymeric nanoparticles, adsorption of drug molecules on the surface of
nanospheres, or formulation of aqueous-core nanocapsules. Table 5 summarizes some of the
advantages and drawbacks of each of these approaches[7].
Nanoparticle-based formulations offer several advantages. First, drug encapsulation
prevents biological macromolecules from degradation in the GI tract, and allows them to reach
the target site in relatively higher concentration. Second, encapsulation may increase the oral
bioavailability of these drugs while minimizing the plasma concentration fluctuations and the
systemic side effects. This is due to the utilization by the nanoparticles, of different uptake
mechanisms such as ‘active transport system’ or ‘endocytosis’, and the ability of the drug to
remain in circulation for a prolonged period of time, mimicking a controlled-release profile.
Third, nano-encapsulating drug molecules significantly decreases the size, allowing more passive
diffusion, and penetration through the biological membranes. The uptake of nanostructures has
been reported to be about 15-250 times greater than that of microparticles in the 1-10 μm range
[31].
Table 5: Nanoparticle-based formulation strategies
Strategy

Entrapment in
polymer
nanoparticles

Advantages
• Drug protection
• Sustained drug release
• Loading efficiency dependent
on the formulation process

Drawbacks
Lack of drug solubility in polymer
Reaction between drug and PACA/monomer
Use of organic solvent
Medium acidification during polyester
degradation
• Rapid degradation of alginate nanoparticles
by cation exchange
•
•
•
•

Adsorption
onto polymer
nanoparticles

Entrapment in
Aqueous Core
Nanoparticles
(ACN) -drug
protection

• Drug not submitted to the
formulation process
• Nature of polymer (charge,
hydrophilicity) influences drug
loading
• No reaction between drug and
polymer  possibility of
modifying the nanoparticle
surface
• Drug solubilized in the core
• Reaction between drug and
monomer is limited
• Low polymer content
• Sustained drug release

•
•
•
•
•

Drug leakage and rapid release
Nanoparticle destabilization by charge mask
Stealth properties modified
Lower biological efficacy
Use of organic solvent

• High energy devices for generating
emulsions and nano-emulsions
• Organic solvent

Several agents belonging to different chemical classes have been explored for their use as
nano-encapsulating agents. These chemical classes with their unique attributes, and current
status of some specific examples are summarized in Table 6; enlisting all the examples and
their current statuses is beyond the scope of this review. Nanoparticulating or nanosizing of
drugs involves a reduction of drug particle sizes to less than 100 nm. Nanoparticulation of drug
particles have been reported to provide several advantages including enhanced drug delivery,
reduction in the amount of expensive Active Pharmaceutical Ingredient (API) required,
protection from biological degradation, and possible achievement of higher specificity with
minimized side effects. Among the popular nanoparticulating techniques are formulation of
liposomes, and the use of nanometric carriers, each with their unique contribution in enhancing
drug delivery via an increase in permeability [27].
Table 6: Nanoparticle encapsulation agents
Category

Examples

Toxicity

Current status

Comments

• Nontoxic and
biodegradable

• Paclitaxelalbumin
(Abraxane®
Approved by
the USFDA
in 2005 for
the
treatment of
breast, lung,
pancreatic,
and small
cell lung

• Synthetic or
natural
• Water-soluble
• Selective drug
accumulation
in tumor tissue
(EPR effect)
• Receptormediated
targeting to
increase
specificity

Polymer based agents
Polymer-drug
conjugates

Natural polymers:
• albumin,
chitosan, and
heparin
Synthetic polymers:
• N-(2hydroxypropyl)methacrylamide
copolymer
(HPMA)

•
•
•

Polystyrenemaleic anhydride
copolymer
Polyethylene
glycol (PEG)
Poly-L-glutamic
acid (PGA)

•

•

•

•

Polymeric
micelles

•
•

Biodegradabl
e and nontoxic

•

Paclitaxel
Genexol-PM
(PEG-poly(D,Llactide)paclitaxel)

cancers [76,
77]
DoxorubicinHPMA
copolymer
(Phase II
trials
completed)
[78]
PaclitaxelPoly
(glutamic
acid) (Phase
II trials
completed)
[79]
PEG-Pglu
(SN38)
(Phase II
trials for
breast
cancer) [80,
81]
Paclical
(Paclitaxel
polymeric
micelle)(
Phase III
completed
for ovarian
cancer) [82]

toward cancer
cells

•
•

•
•
•
•

Dendrimers
•

Poly(amidoamin
e)
•

Cationic
dendrimers
exhibit
hemolytic
toxicity,
cytotoxicity
and
hematologica
l toxicity[83]
Neutral and
negatively
charged

•

Docetaxeldendrimer
conjugate
(DEPTMDocetaxel in
Phase I
trials for
advanced
metastatic
cancer)[84]

•

•

Amphiphilic
block
copolymers
Suitable
carrier for
waterinsoluble
drugs
Biocompatible
, selfassembling
Ease of
modification
Targeting
potential
Synthetic
polymeric
macromolecul
e with
nanometer
dimensions
Monodisperse
size,
modifiable
surface
functionality
 high

dendrimers
are nontoxic[83]

•
•

•
•

structural and
chemical
homogeneity
Multivalency
Water
solubility and
biodistribution
can be
modified
Internal cavity
Controlled
degradation

Lipid based agents
•
Liposomes
•
•

Pegylated
liposomes
Non-pegylated
liposomes

•

Viral
nanoparticles

•
•
•
•

•
Cowpea mosaic
virus
Cowpea chlorotic
mottle virus
•
Canine
parvovirus
Bacteriophages

•
Carbon
nanotubes
-

Cationic
liposomes
(nonpegylated
liposomes)
has shown to
cause dose
dependent
toxicity and
pulmonary
inflammation
in mice[85]

•

Could elicit
immune
response in
host[88]
Cowpea
mosaic virus
is reported to
be safe [89]
Viral
nanoparticles
containing
iron oxide
are reported
to be
toxic[90]

•

Reported to
have multiple
toxicities
depending on
the surface
charge,
shape, length,
diameter,

•

Doxil
(Doxorubici
n liposomes
approved
for the
treatment of
Kaposi’s
sarcoma,
ovarian
cancer and
breast
cancer)[86,
87]
Emerging
field with
applications
in disease
prevention,
diagnosis,
monitoring
and
therapy[91]

•
•
•

•

•

•
•

Emerging
area of
research

•
•

Amphiphilic,
biocompatible
Ease of
modification
Targeting
potential

Multifunction
al with
specific tumor
targeting
Multivalency
– ability to
allow various
surface
modifications
Defined
geometry and
uniformity
Biological
compatibility
and inert
nature

Use of
benzene ring
Multifunction
al

agglomeratio
n and
purity[91, 92]

Liposomes and other nanometric carriers
Liposomes are generally described as lipid-based microscopic vesicles with sizes ranging from
50 nm to over 100μm. Liposomes may possess a negative, positive, or a neutral surface-charge
depending on their composition. In addition, depending on their size, liposomes may be
categorized as unilamellar vesicles, or in the presence of more than one bilayers, multilamellar
vesicles [93]. The lipid bilayers of the liposomes possess both hydrophilic and lipophilic
properties, similar to that observed in the phospholipid bilayer in human cells. These properties
provides liposomes with a specific advantage with respect to increasing permeability by
facilitating enhanced interactions between the drug and the cell membrane. Enhanced
permeability with liposomes is achieved via one or more of the four mechanisms: adsorption,
endocytosis, fusion, and lipid transfer. Additionally, derivatized liposomes such as pegylated
liposomes have been reported to display a prolonged drug circulation, and a slower release of
drug molecules similar to controlled-release formulations [94, 95]. Liposomes are also reported
to possess the ability to provide target-site specificity, as demonstrated by pegylated horseradish-peroxidase loaded liposomes targeting the brain capillary endothelial cells [96].
Another nanotechnology-based approach for permeability enhancement of drugs is the
use of nanometric carriers. This approach involves adsorbing, entrapping, or covalently attaching
the drug molecules to sub-micron sized particulate carriers in an attempt to improve the drug
permeability. Among the reported advantages of this approach are, ease of passage across even
the smallest of the capillary vessels, achievement of higher penetration into the cells and organs,
prolonged plasma circulation by avoiding phagocytic clearance, improved therapeutic effects of
drugs, and the ease of functional modifications for improving stability [31]. Current research
with regards to utilizing this approach for enhanced drug delivery is primarily focused on
achieving target specificity, improving the drug delivery capacity, and the use of a combination
of carrier materials to improve drug delivery efficiency. Among the commonly employed
nanometric carrier materials include, poly-lactic acid (PLA), poly-glycolic acid (PGA), and polylactide-coglycolide (PLGA).

Smart drug delivery systems, polymer-drug conjugates, and multifunctional carrier systems
Achieving acceptable drug permeation and accumulation in the target tissue or organ calls for
designing a drug delivery system that is multifunctional, and more specifically possessing a
property of switching ‘on’ or ‘off’ certain functions when required [31]. While several attempts
have been made to formulate such a drug delivery system utilizing nanotechnology based
approaches such as liposomes or nanoparticles, only few successes have been reported [97].
The Smart Drug Delivery Systems (SDDS), also known as the stimuli-sensitive delivery
systems function on a principle of ‘rapid transition of the physical-chemical properties of a
polymer system upon contact with a stimulus’, the stimulus being either physical, chemical, or
biological, to trigger a desired drug release [31]. A commonly employed approach for the
development of SDDS is through the use of polymer micelles. The polymeric micelles contain
both hydrophilic, and lipophilic domains, and when used to encapsulate hydrophilic drugs, are
known to increase the permeability via passive diffusion. The release of drug occurs upon the
degradation of the micellar domains in-vivo. A specific example of micelle forming polymeric
agent is Poly (ethylene glycol)-b-polyhistidine (PEG-b-PHis). A unique property of PEG-b-PHis
is the ability to adjust its pKa by changing its molecular weight. Several studies report successful
utilization of PEG-b-PHis to prepare SDDS, and achieve targeted and controlled drug delivery
[98, 99]. Higher localized drug accumulation have been achieved at the desired target site even
with the parenteral administration of SDDS [100]. Chu et al. prepared a SDDS which consisted
of a glucose-sensitive microcapsule with a porous membrane, with linear-grafted polyacrylic
acid (PAAC) chains, and covalently bound glucose oxidase enzymes in the membrane pores
acting as functional gates [101]. The study results showed that the prepared SDDS provided a
self-regulated drug delivery systems capable of releasing insulin in response to changes in the
plasma glucose concentration.
The polymer-drug conjugates has been a successfully utilized approach for improving the
delivery of several drugs. However, this approach is mainly employed to improve the
solubilization of drugs, rather than for improving permeability. Polymer-drug conjugates
typically consists of water-soluble polymers that attach to the drug molecules, forming a
conjugate with increased aqueous solubility and distribution. An advantage of utilizing polymerdrug conjugates is the formation of colloidal particles which may prolong the drug circulation
time [31]. Multifunctional drug delivery systems (MDDS) are the systems that possess more than

one of the functional properties observed with the nanotechnology based approaches. These
delivery systems exhibit properties such as stimuli-sensitivity, passive/active drug localization at
targeted site, ability to achieve higher bioavailability, and/or increased blood circulation time. An
example of a MDDS would be a mixture of PLA-b-PEG-b-PHis-biotin and PEG-b-PHis block
copolymers [68].
Nanotechnology-based approaches provides a plethora of options for enhancing drug
delivery via different routes, i.e. oral, parenteral, pulmonary, topical etc. Although parenteral
formulations are devoid of challenges related to drug permeability (since they are directly
injected into blood stream), it is still important to evaluate the benefits of using nanoparticle
based formulations to ensure the distribution/bioavailability of the drug at the site of action. Zara
et al. compared the pharmacokinetics of doxorubicin incorporated as ion-pair into Solid-Lipid
Nanospheres (SLN) with that of the commercial solution of the drug in laboratory animals [102].
They observed that SLN showed a markedly higher concentration of doxorubicin in the blood,
lung, spleen, and brain, at each time point than observed with the commercial solution. The study
also found that the SLN-treated rats showed a lower doxorubicin concentration in liver, heart and
kidney. Additionally, the results showed that SLN increased the area under the curve (AUC) of
doxorubicin compared to a conventional doxorubicin solution. Since oral administration is the
most preferred route of administration, it is also the focus of several nanotechnology-based
studies for improving drug bioavailability. Kalaria et al. prepared and pharmacokinetically
evaluated doxorubicin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles [103]. They
found that the doxorubicin-loaded nanoparticles demonstrated a significant (363%) increase in
the bioavailability of doxorubicin, and a six fold increase in its T max.
Pulmonary drug delivery is another area that has benefitted from nanotechnology based
approaches. Here, however, a nanoparticulate strategy via micronization of drug particles rather
than drug encapsulation is utilized. Smaller drug sizes enable better penetration in the lung either
via i.v. administration (through microspheres), nebulized solutions, or dry powder inhalations.
An example of nanoparticle utilization for pulmonary administration is the microemulsion
system based on water/lecithin/propanol/iso-octane [104]. The small size of nanoparticles allows
them to be the ideal candidates for pulmonary administration. However, the effects of
microsizing/nanosizing on the manufacturability, stability, and the safety of the drug products
need further research and analysis. Due to the small size and higher penetration observed with

nanotechnology based products, nanoparticles have also found applications in topically
administered products. In comparison to the conventional drug molecules, nanoparticles result in
a more unison drug particle and larger number of particles, leading to a higher occlusion factor
and skin penetration (Figure 4). Moreover, compared to conventional formulations, a smaller
dose is required with nanoparticles. This results in a significant reduction in the occurrence of
irritation, dryness, itching, and/or burning sensation that can occur with conventional dosage
forms.
A promising new application of nanoparticles is the possibility of achieving a target
specific drug delivery. Gao et al. investigated the multivalent effect for up-regulating the
intracerebral delivery of nanoparticles via receptor-mediated transcytosis [105]. They prepared
nanoparticles labeled with near-infrared (NIR) fluorophore and different numbers of angiopep-2
peptides that specifically target low-density lipoprotein receptor-related protein (LRP) on the
blood brain barrier (BBB). The in-vivo NIR image analysis showed that the multimetric
association between the angiopep-2 peptides labeled on the nanoparticle, and the LRP receptors
on the BBB significantly increased the intracerebral uptake of the nanoparticles.
Hybrid or combination approaches
With the advancement of technology, several studies employing a combination of one or more
approaches above to improve drug permeability have been explored. Fattal et al. studies the
effect of hybridization of polyalkylcynoacrylate nanoparticle and an ion-pairing agent, cation
hydrophobic detergent (CTAB) on the delivery of antisense oligonucleotides (ON) in modulating
gene expression [106]. ON was loaded into the polyalkylcyanoacrylate nanoparticle that was
formed via an emulsion polymerization process. The obtained complex was then coated with
CTAB to create a lipophilic nanoparticle-ion paired complex. The functional characterization of
this complex was then carried out via in-vitro and in-vivo analysis. The in vitro analysis showed
an increase in the cellular uptake of the drug complex, as it survives the nuclease attack in the
cell culture media and is actively taken up via the endocytotic/phagocytotic pathway. The invivo analysis demonstrated an increased stability of the drug complex in plasma and liver. While
this method of hybridization between nanoparticle and the ion-pairing approach did not
demonstrate an increased drug permeability, and instead increased the active uptake of the drug,
it is still a feasible method to consider.

Another example of hybridization/combination of nanoparticle and ion-pairing approach
is the formation of an insulin-sodium deoxycholate complex with an aim to promote the oral
delivery of insulin [41]. In this study, an insulin-deoxycholate complex (Ins-SD-Comp) was first
formed by the hydrophobic ion-pairing method to increase the lipophilicity of insulin. This
complex was also hypothesized to enhance the bioavailability of insulin, as sodium deoxycholate
is naturally produced by the liver and undergoes enterohepatic circulation up to 20 times a day.
This Ins-SD-Comp was then encapsulated in poly (lactide-co-glycolide) (PLGA) nanoparticle via
emulsion solvent diffusion method to form Ins-SD-Comp-PLGA-NP, to prevent physiological
degradation and enable oral administration. The hypoglycemic effects of this hybrid complex
were analyzed by the in vivo bioassay. The results showed that this hybrid complex demonstrated
a statistically significant plasma glucose reduction when compared to oral administration of
saline-free insulin solution.
Conclusions
GI absorption of the low permeability compounds such as those belonging to the BCS Class III
or molecules with similar properties is an area of extensive research. For these drugs, the
intestinal membrane permeability is expected to be the rate-limiting step in the overall drug
absorption process. Amongst the various approaches used for improving the permeability
include, prodrugs, permeation enhancers, ion-pairing, and nanotechnology based approaches.
The use of prodrugs or targeting carrier-mediated transport has proven to be a relatively
successful in improving the permeability. Ion-pairing approach has yielded positive results in
transdermal and parenteral drug delivery; however, further research for the application of this
approach for oral delivery is still underway.
Nanotechnology-based approach have shown to provide a promising technology to
enhance the permeability of the drugs. Both the nanoencapsulation and nanosizing strategies
result in significant reduction in the particle size, resulting in improved drug permeability. While
the majority of research utilizing nanotechnology is still under clinical trials, the current results
from different routes of administration have demonstrated positive outcomes. Similar to ionpairing approach, further research is required to assess the safety profile of nanotechnologybased products and the ease of their manufacturing. Once thought impossible, the hybridization
of several approaches for improving drug permeability is now feasible. While the initial studies
have demonstrated a success in the formation of nanoparticle-ion-paired hybrid complexes and

stable activity, it is usually either the ion-pairing effect or the nanoparticle effect that is found to
be the key permeability enhancer. Nonetheless, further advancement in the technology and
refinement of approaches will certainly make the hybrid-complexes a successful strategy in
improving drug permeability.
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